Home > Cardiology > More evidence links MCP-1 levels to cardiovascular mortality

More evidence links MCP-1 levels to cardiovascular mortality

JAMA Cardiology
Reuters Health - 12/11/2020 - Higher circulating levels of monocyte-chemoattractant protein-1 (MCP-1) are associated with higher long-term cardiovascular mortality in individuals free of overt heart disease, a meta-analysis suggests. "By complementing evidence from previous genetic and experimental studies, these results provide additional support for a key role of MCP-1 in cardiovascular disease development," note Dr. Martin Dichgans of Ludwig-Maximilians-University in Munich and colleagues in JAMA Cardiology. The meta-analysis included seven cohort studies involving more than 21,000 individuals without known heart disease (mean age, 54; 47% men). Mean follow-up was 15.3 years. In adjusted models (age, sex, race/ethnicity), higher baseline MCP-1 levels were associated with increased risk of coronary heart disease (hazard ratio per one standard-deviation increment in MCP-1 levels, 1.06), nonfatal myocardial infarction (HR, 1.07), and cardiovascular death (HR,...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on